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Ceftolozane/tazobactam, a novel antimicrobial agent with activity against Pseudomonas aeruginosa (including drug-resistant
strains) and other common Gram-negative pathogens (including most extended-spectrum--lactamase [ESBL]-producing En-
terobacteriaceae strains), and comparator agents were susceptibility tested by a reference broth microdilutionmethod against
7,071 Enterobacteriaceae and 1,971 P. aeruginosa isolates. Isolates were collected consecutively from patients in 32 medical cen-
ters across the United States during 2011 to 2012. Overall, 15.7% and 8.9% of P. aeruginosa isolates were classified as multidrug
resistant (MDR) and extensively drug resistant (XDR), and 8.4% and 1.2% of Enterobacteriaceaewere classified as MDR and
XDR. No pandrug-resistant (PDR) Enterobacteriaceae isolates and only one PDR P. aeruginosa isolate were detected. Ceftolo-
zane/tazobactam was the most potent (MIC50/90, 0.5/2g/ml) agent tested against P. aeruginosa and demonstrated good activity
against 310MDR strains (MIC50/90, 2/8g/ml) and 175 XDR strains (MIC50/90, 4/16g/ml). Ceftolozane/tazobactam exhibited
high overall activity (MIC50/90, 0.25/1g/ml) against Enterobacteriaceae and retained activity (MIC50/90, 4/>32g/ml) against
many 601MDR strains but not against the 86 XDR strains (MIC50,>32g/ml). Ceftolozane/tazobactam was highly potent
(MIC50/90, 0.25/0.5g/ml) against 2,691 Escherichia coli isolates and retained good activity against most ESBL-phenotype E. coli
isolates (MIC50/90, 0.5/4g/ml), but activity was low against ESBL-phenotype Klebsiella pneumoniae isolates (MIC50/90, 32/>32
g/ml), explained by the high rate (39.8%) of meropenem coresistance observed in this species phenotype. In summary, ceftolo-
zane/tazobactam demonstrated high potency and broad-spectrum activity against many contemporary Enterobacteriaceae and
P. aeruginosa isolates collected in U.S. medical centers. Importantly, ceftolozane/tazobactam retained potency against many
MDR and XDR strains.
Ceftolozane/tazobactam is a novel antibacterial agent with ac-tivity against Pseudomonas aeruginosa, including drug-resis-
tant strains, and other common Gram-negative pathogens, in-
cluding most extended-spectrum--lactamase (ESBL)-producing
Enterobacteriaceae strains (1). Ceftolozane is a novel antibacterial
agent with potent activity (compared with ceftazidime) against P.
aeruginosa, including drug-resistant strains, and Enterobacteria-
ceae (with potency similar to that of other oxyimino-aminothia-
zolyl cephalosporins) (1–6). However, as with other cephalospo-
rins, ceftolozane’s activity is compromised in bacteria producing
ESBLs, stably derepressed AmpC -lactamases, and carbapen-
emases (1, 7). Tazobactam, a penicillanic acid-sulfone, is a well-
established -lactamase inhibitor that broadens the coverage of
-lactam agents (8). Unlike clavulanate and sulbactam, tazobac-
tam is a moderate inhibitor of inducibly and constitutively ex-
pressed AmpC enzymes, although this activity is strain dependent
and is less potent against strains with totally derepressed AmpC
-lactamases (9).
During the past decade, nosocomial infections caused by En-
terobacteriaceae and P. aeruginosa in intensive care units world-
wide have been increasing in prevalence along with increases in
antimicrobial resistance and associated increases in morbidity and
mortality (10, 11). Empirical and targeted therapies to cover in-
fections with these organisms are increasingly limited. Ceftolo-
zane/tazobactam exploits ceftolozane’s potent activity against P.
aeruginosa and Enterobacteriaceae and broadens ceftolozane’s
spectrum of activity against Enterobacteriaceae (1), hence making
it an attractive option for clinical development for treatment of
some infections caused by multidrug-resistant (MDR) Gram-neg-
ative bacteria. Ceftolozane/tazobactam is currently in phase III
trials for the treatment of complicated urinary tract infections,
complicated intra-abdominal infections, and nosocomial bacte-
rial pneumonia. In the present study, we evaluated the potency of
ceftolozane/tazobactam and comparator drugs tested for the first
time against a large, contemporary (2011–2012) collection of clin-
ically collected Enterobacteriaceae and P. aeruginosa isolates ob-
tained from patients in U.S. hospitals.
MATERIALS AND METHODS
Sampling sites and organisms. A total of 7,071 Enterobacteriaceae and
1,971 P. aeruginosa isolates were consecutively collected over 2 years (Jan-
uary 2011 to December 2012) from 32 medical centers located across all
nine U.S. census regions. All organisms were isolated from documented
infections, and only one strain per patient infection episode was included
in the surveillance collection. The isolates were derived primarily from
bloodstream infections, skin and skin-structure infections (SSSI), and
pneumonia in hospitalized patients, urinary tract infections in hospital-
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ized patients, and intra-abdominal infections according to a common
surveillance design.
Antimicrobial susceptibility testing. MIC values were determined
using the reference Clinical and Laboratory Standards Institute (CLSI)
broth microdilution method (M07-A9) (12). Quality control (QC) ranges
and interpretive criteria for comparator compounds used the CLSI M100-
S23 guidelines (13). The ESBL phenotype was defined as a MIC of 2
g/ml for ceftazidime or ceftriaxone or aztreonam (13). To better evalu-
ate the activities of ceftolozane/tazobactam against-lactam-resistantEn-
terobacteriaceae and P. aeruginosa, strains were stratified by patterns of
susceptibility to ceftazidime and meropenem. MDR, extensively drug-
resistant (XDR), and pandrug-resistant (PDR) bacteria were classified as
such per recently recommended guidelines (14) using the following anti-
microbial class representative agents and CLSI interpretive criteria (13):
for P. aeruginosa, ceftazidime (MIC of 16 g/ml), meropenem (4
g/ml), piperacillin-tazobactam (32/4 g/ml), levofloxacin (4 g/
ml), gentamicin (8g/ml), and colistin (4g/ml); and for Enterobac-
teriaceae, ceftriaxone (2 g/ml), meropenem (2 g/ml), piperacillin-
tazobactam (32/4 g/ml), levofloxacin (4 g/ml), gentamicin (8
g/ml), tigecycline (4 g/ml), and colistin (4 g/ml). Classifications
were based on the following recommended parameters: MDR nonsus-
ceptible to1 agent in3 antimicrobial classes; XDR nonsusceptible
to1 agent in all but2 antimicrobial classes; PDR nonsusceptible to
all antimicrobial classes (14).
RESULTS
Ceftolozane/tazobactam activity against Enterobacteriaceae. Cef-
tolozane/tazobactam demonstrated high overall activity (MIC50,
0.25g/ml; MIC90, 1g/ml) against 7,071 Enterobacteriaceae iso-
lates collected in the United States during 2011 to 2012 (Table 1
and Table 2). Using MIC90 values, ceftolozane/tazobactam
showed potency identical to that of cefepime, was 16-fold more
active than ceftazidime and piperacillin-tazobactam (MIC90 for
both, 16g/ml), was at least 16-fold more potent than ceftriaxone
(MIC90,8 g/ml), and was second in potency against all tested
compounds only to meropenem (MIC90,0.06 g/ml; Table 2).
Against 601 (8.5%) MDR isolates, meropenem (MIC50/90,
0.06/8 g/ml; 77.0% susceptible), ceftolozane/tazobactam
(MIC50/90, 4/32 g/ml), tigecycline (MIC50/90, 0.5/2 g/ml;
92.3% susceptible), and colistin (MIC50/90, 0.5/4 g/ml) were
the only agents tested to retain activity at the MIC50 level (Table 2).
Ceftolozane/tazobactam was not active against most XDR strains
(n 86; 1.2%) (MIC50/90,32/32 g/ml), with tigecycline be-
ing the most active agent (87.1% susceptible), followed by mero-
penem and gentamicin, with low susceptibility rates of only 22.1%
and 20.9%, respectively (Table 2). No PDR Enterobacteriaceae iso-
lates were collected in this study.
Ceftolozane/tazobactam was highly potent (MIC50/90, 0.25/0.5
g/ml), inhibiting 99.0% of 2,691 Escherichia coli isolates at a MIC
of4g/ml and 100.0% of 2,364 non-ESBL-phenotype isolates at
a MIC of2 g/ml (Table 1). Similarly, ceftolozane/tazobactam
activity was high against non-ESBL-phenotype Klebsiella pneu-
moniae, Klebsiella oxytoca, and Proteus mirabilis (MIC90 for all
three, 0.5 g/ml; Table 1). Although ceftolozane/tazobactam was
active against most ESBL-phenotype E. coli isolates (MIC50/90,
0.5/4 g/ml), its potency was much lower against ESBL-pheno-
type K. pneumoniae (MIC50/90, 32/32 g/ml; Table 1). This ob-
served lower activity for ceftolozane/tazobactam in ESBL-pheno-
type K. pneumoniae can be explained by the higher rate of
meropenem resistance (i.e., carbapenemases) observed in this phe-
notype (39.8%) compared with ESBL-phenotype E. coli (1.5%;
Table 2), supported by the higher activity (MIC90, 1g/ml) observed
against meropenem-susceptible K. pneumoniae (Table 1).
Tested against Enterobacter spp., Citrobacter spp., and Serratia
spp., ceftolozane/tazobactam exhibited 8-fold-greater activity
(MIC50, 0.25 to 0.5 g/ml) than piperacillin-tazobactam (MIC50,
2 to 4g/ml), activity similar to that of ceftriaxone (MIC50, 0.12 to
0.25g/ml) and ceftazidime (MIC50, 0.25g/ml for all three gen-
era), and activity similar to or lower than that of cefepime (MIC50,
0.5 g/ml; Table 2). Ceftolozane/tazobactam was also very ac-
tive (MIC50/90, 0.25/1 g/ml) against 368 indole-positive Proteus
spp. (Table 1).
Ceftolozane/tazobactam activity against P. aeruginosa. Cef-
tolozane/tazobactam was the most potent (MIC50/90, 0.5/2g/ml)
agent tested against 1,971 P. aeruginosa isolates, inhibiting 96.1%
at a MIC of4 g/ml (Tables 3 and 4). Ceftolozane/tazobactam
was at least 4-fold more active than ceftazidime (MIC50/90, 2/32
g/ml), at least 8-fold more active than cefepime (MIC50/90, 4/16
g/ml), at least 16-fold more active than piperacillin-tazobactam
(MIC50/90, 8/64 g/ml), and slightly more potent than mero-
penem (MIC50/90, 0.5/8g/ml) when tested against the entire col-
lection of P. aeruginosa isolates (Table 4). After colistin (MIC50/90,
1/2 g/ml; 98.4% susceptible), ceftolozane/tazobactam was the
most active (MIC50/90, 2/8 g/ml) agent tested against 310 MDR
P. aeruginosa isolates, with resistance for all other agents ranging
from 36.5% for gentamicin to 70.6% for levofloxacin (Table 4).
Similarly, against 175 XDR strains, ceftolozane/tazobactam re-
tained activity (MIC50/90, 4/16g/ml), whereas resistance to other
agents was high—ranging from 49.7% for gentamicin to 88.0%
for levofloxacin (Table 4). Most XDR strains remained susceptible
to colistin (97.7% susceptible), while in contrast, high levels of
resistance to ceftazidime (73.7% resistant) and meropenem
(76.0% resistant) were observed (Table 4). Only one PDR P.
aeruginosa strain was detected, and ceftolozane/tazobactam dem-
onstrated no observable activity (MIC, 32 g/ml; Table 3)
against this strain. Ceftolozane/tazobactam also had good activity
against many ceftazidime-nonsusceptible (MIC50/90, 4/8 g/ml),
meropenem-nonsusceptible (MIC50/90, 1/8 g/ml), piperacillin-
tazobactam-nonsusceptible (MIC50/90, 2/8 g/ml), cefepime-
nonsusceptible (MIC50/90, 4/8 g/ml), levofloxacin-nonsuscep-
tible (MIC50/90, 1/8 g/ml), and gentamicin-nonsusceptible
(MIC50/90, 1/8 g/ml) isolates (Table 3). Ceftolozane/tazobactam
also had moderate activity against many isolates with combined
ceftazidime and meropenem nonsusceptibility (MIC50/90, 4/32
g/ml) and combined ceftazidime and meropenem and pipera-
cillin-tazobactam nonsusceptibility (MIC50/90, 4/32 g/ml; Ta-
ble 3).
DISCUSSION
Resistance mechanisms in Enterobacteriaceae and P. aeruginosa
are extremely diverse, and there is currently no antimicrobial
agent or combination that allows complete coverage of these im-
portant pathogens in the hospital setting. In in vitro studies to
date, ceftolozane/tazobactam has demonstrated the greatest over-
all in vitro activity, compared with other agents tested, against this
combined group of Gram-negative pathogens (1, 7, 15). The data
from this large multicenter U.S. surveillance study confirm the
data presented in earlier studies and demonstrate that ceftolo-
zane/tazobactam had high in vitro potency and a broad spectrum
of activity against many nosocomial isolates of Enterobacteriaceae
and P. aeruginosa circulating in the United States during 2011 and
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2012. In addition, this larger set of contemporary data supports
the previously reported activity against a collection of ceftazi-
dime- and/or carbapenem-resistant Enterobacteriaceae and P.
aeruginosa isolates (1).
TABLE 2 Antimicrobial activity of ceftolozane/tazobactam and various
comparator agents against Enterobacteriaceae collected in the U.S.
during 2011 to 2012
Organism(s) and
antimicrobial agenta (no.
tested) MIC50 MIC90
%
susceptibleb
%
resistantb
Enterobacteriaceae—all
isolates (7,071)
Ceftolozane/tazobactam 0.25 1 —c —
Ceftazidime 0.12 16 88.1 10.5
Ceftriaxone 0.06 8 85.2 13.8
Cefepime 0.5 1 94.0 5.0
Meropenem 0.06 0.06 98.0 1.8
Piperacillin-tazobactam 2 16 90.9 5.8
Aztreonam 0.12 16 88.0 10.5
Levofloxacin 0.12 4 81.9 16.1
Gentamicin 1 4 90.7 8.2
Tigecyclined 0.25 1 98.2 0.1
Colistin 0.5 4 — —
Enterobacteriaceae—MDR
(601)
Ceftolozane/tazobactam 4 32 — —
Ceftazidime 32 32 22.0 71.7
Ceftriaxone 8 8 11.0 87.7
Cefepime 16 16 46.9 44.1
Meropenem 0.06 8 77.0 20.5
Piperacillin-tazobactam 64 64 34.6 46.3
Aztreonam 16 16 22.0 74.2
Levofloxacin 4 4 17.8 72.9
Gentamicin 8 8 40.8 50.1
Tigecyclined 0.5 2 92.3 0.2
Colistin 0.5 4 — —
Enterobacteriaceae—XDR
(86)
Ceftolozane/tazobactam 32 32 — —
Ceftazidime 32 32 2.3 96.5
Ceftriaxone 8 8 0.0 100.0
Cefepime 16 16 15.1 73.3
Meropenem 8 8 22.1 70.9
Piperacillin-tazobactam 64 64 2.3 81.4
Aztreonam 16 16 3.5 93.0
Levofloxacin 4 4 0.0 93.0
Gentamicin 8 8 20.9 61.6
Tigecyclined 0.5 4 87.1 0.0
Colistin 4 4 — —
E. coli, ESBL phenotype
(327)
Ceftolozane/tazobactam 0.5 4 — —
Ceftazidime 16 32 31.8 55.7
Ceftriaxone 8 8 8.3 90.2
Cefepime 16 16 44.5 48.8
Meropenem 0.06 8 97.6 1.5
Piperacillin-tazobactam 8 64 77.4 13.5
Aztreonam 16 16 23.2 63.9
Levofloxacin 4 4 22.6 75.5
Gentamicin 2 8 63.0 36.7
Tigecyclined 0.12 0.25 100.0 0.0
Colistin 0.25 0.5 — —
K. pneumoniae, ESBL
phenotype (244)
Ceftolozane/tazobactam 32 32 — —
TABLE 2 (Continued)
Organism(s) and
antimicrobial agenta (no.
tested) MIC50 MIC90
%
susceptibleb
%
resistantb
Ceftazidime 32 32 5.3 88.5
Ceftriaxone 8 8 5.3 93.4
Cefepime 16 16 27.9 60.7
Meropenem 0.06 8 59.0 39.8
Piperacillin-tazobactam 64 64 25.4 65.2
Aztreonam 16 16 7.8 91.0
Levofloxacin 4 4 20.1 76.6
Gentamicin 4 8 50.8 39.8
Tigecyclined 0.5 2 97.1 0.0
Colistin 0.5 4 — —
Enterobacter spp. (1,029)
Ceftolozane/tazobactam 0.25 8 — —
Ceftazidime 0.25 32 75.6 22.1
Ceftriaxone 0.25 8 71.6 25.9
Cefepime 0.5 2 96.3 2.6
Meropenem 0.06 0.06 98.6 1.1
Piperacillin-tazobactam 4 64 81.5 8.1
Aztreonam 0.12 16 76.9 19.2
Levofloxacin 0.12 0.5 94.7 3.9
Gentamicin 1 1 94.8 4.3
Tigecyclined 0.25 0.5 98.5 0.0
Colistin 0.5 4 — —
Citrobacter spp. (381)
Ceftolozane/tazobactam 0.25 8 — —
Ceftazidime 0.25 32 84.8 15.2
Ceftriaxone 0.12 8 84.3 15.2
Cefepime 0.5 1 97.4 1.1
Meropenem 0.06 0.06 97.9 1.8
Piperacillin-tazobactam 2 64 87.1 7.9
Aztreonam 0.12 16 84.8 13.4
Levofloxacin 0.12 2 91.9 5.0
Gentamicin 1 1 95.5 4.2
Tigecyclined 0.12 0.5 100.0 0.0
Colistin 0.5 1 — —
Serratia spp. (573)
Ceftolozane/tazobactam 0.5 1 — —
Ceftazidime 0.25 0.5 97.7 1.7
Ceftriaxone 0.25 1 91.4 6.8
Cefepime 0.5 0.5 99.1 0.3
Meropenem 0.06 0.06 99.1 0.5
Piperacillin-tazobactam 2 4 96.9 0.9
Aztreonam 0.12 0.5 97.5 2.3
Levofloxacin 0.12 0.5 96.5 1.0
Gentamicin 1 2 97.7 2.3
Tigecyclined 0.5 1 99.0 0.3
Colistin 4 4 — —
a Abbreviations: MDR, multidrug resistant; XDR, extensively drug resistant; PDR, pan-
drug resistant; ESBL, extended-spectrum -lactamase.
b According to CLSI interpretive criteria (13).
c —, no published interpretive criteria.
d In the absence of CLSI interpretive criteria, U.S. FDA interpretive criteria were applied
(Tygacil Product Insert, 2012).
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For this investigation, as described in Materials and Methods,
we classified MDR, XDR, and PDR for both Enterobacteriaceae
and P. aeruginosa according to guidelines recently published by an
international expert panel (14). To achieve this, we tested repre-
sentative antimicrobials from different classes in our laboratory to
determine nonsusceptibility within each class. In addition, we
used current (2013) CLSI MIC interpretive criteria to determine
nonsusceptibility (13). It should be noted that current (2013)
European Committee on Antimicrobial Susceptibility Testing
(EUCAST) interpretive criteria (16) differ from the CLSI interpre-
tive criteria for many of the organism/antimicrobial combinations
(for example, for Enterobacteriaceae, nonsusceptibility to mero-
penem is 2 g/ml by CLSI and 4 g/ml by EUCAST). With
these caveats, these data show that, although the level was reduced,
ceftolozane/tazobactam retained good activity against MDR and
XDR strains of P. aeruginosa and MDR strains of Enterobacteriace-
ae— but low activity against most strains of XDR Enterobacteria-
ceae due to the high prevalence of carbapenemase-producing K.
pneumoniae in the XDR population (Table 2). This is in contrast
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TABLE 4 Antimicrobial activity of ceftolozane/tazobactam and various
comparator agents against P. aeruginosa isolates collected in the United
States during 2011 to 2012
P. aeruginosa resistance
status (no. of isolates
tested) and antimicrobial
agenta MIC50 MIC90
%
susceptibleb
%
resistantb
All isolates (1,971)
Ceftolozane/tazobactam 0.5 2 —c —
Ceftazidime 2 32 82.9 13.7
Cefepime 4 16 82.4 8.6
Meropenem 0.5 8 80.3 13.9
Piperacillin-tazobactam 8 64 76.8 13.7
Aztreonam 8 16 68.5 19.2
Levofloxacin 0.5 4 74.9 19.1
Gentamicin 1 8 89.2 7.7
Colistin 1 2 99.1 0.2
MDR (310)
Ceftolozane/tazobactam 2 8 — —
Ceftazidime 32 32 22.6 60.6
Cefepime 16 16 22.5 38.7
Meropenem 8 8 19.4 64.5
Piperacillin-tazobactam 64 64 11.0 60.0
Aztreonam 16 16 9.0 69.0
Levofloxacin 4 4 15.2 70.6
Gentamicin 4 8 53.5 36.5
Colistin 1 2 98.4 0.3
XDR (175)
Ceftolozane/tazobactam 4 16 — —
Ceftazidime 32 32 9.1 73.7
Cefepime 16 16 10.9 52.0
Meropenem 8 8 7.4 76.0
Piperacillin-tazobactam 64 64 2.3 74.9
Aztreonam 16 16 4.6 72.6
Levofloxacin 4 4 2.9 88.0
Gentamicin 8 8 38.9 49.7
Colistin 1 2 97.7 0.6
a Abbreviations: MDR, multidrug resistant; XDR, extensively drug resistant (14).
b According to CLSI interpretive criteria (13).
c —, no published interpretive criteria.
Ceftolozane/Tazobactam U.S. Surveillance (2011-2012)
December 2013 Volume 57 Number 12 aac.asm.org 6309
to other agents (except colistin) that demonstrated reduced sus-
ceptibility (MDR/XDR)—22.6/9.1% ceftazidime-susceptible and
19.4/7.4% meropenem-susceptibleP. aeruginosa (Table 3) isolates
and 22.0/2.3% ceftazidime-susceptible and 77.0/22.1% mero-
penem-susceptible Enterobacteriaceae isolates (Table 1). Overall,
in this U.S. surveillance study performed from 2011 through 2012,
15.7% of P. aeruginosa isolates were classified as MDR and 8.9%
were classified as XDR (Table 3), and 8.4% of Enterobacteriaceae
isolates were classified as MDR and only 1.2% as XDR (Table 1).
Only one strain was classified as PDR. In this study, ceftolozane/
tazobactam activity was most compromised against the XDR En-
terobacteriaceae (only 1.2% of Enterobacteriaceae isolates).
In summary, these data for ceftolozane/tazobactam that have
been collected over 2 years from 32 medical centers located across
all nine U.S. census regions demonstrate high potency and broad-
spectrum activity of this antibacterial agent tested against contem-
porary Enterobacteriaceae and P. aeruginosa strains. Importantly,
ceftolozane/tazobactam retained clear activity against many MDR
and XDR strains. The in vitro surveillance data presented here,
coupled with favorable results published from pharmacokinetic,
safety, animal infection, and in vitro studies (15, 17–20), suggest
the potential usefulness of ceftolozane/tazobactam for the treat-
ment of some infections caused by MDR Gram-negative organ-
isms and warrant further clinical development.
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